Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,548.1	$ 2,326.5
Marketable securities	1,960.2	2,568.6
Accounts receivable, net	1,567.5	1,441.6
Due from anti-CD20 therapeutic programs	518.0	300.6
Inventory	1,007.2	1,001.6
Other current assets	967.0	1,093.3
Total current assets	7,568.0	8,732.2
Marketable securities	3,062.0	2,829.4
Property, plant and equipment, net	2,995.9	2,501.8
Intangible assets, net	4,019.4	3,808.3
Goodwill	4,127.5	3,669.3
Investments and other assets	1,300.4	1,335.8
Total assets	23,073.2	22,876.8
Current liabilities:
Current portion of notes payable and other financing arrangements	573.2	4.7
Taxes payable	121.3	231.9
Accounts payable	298.7	279.8
Accrued expenses and other	2,455.2	2,903.5
Total current liabilities	3,448.4	3,419.9
Notes payable and other financing arrangements	5,938.3	6,512.7
Deferred tax liability	120.7	93.1
Other long-term liabilities	716.9	722.5
Total liabilities	10,224.3	10,748.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	59.2	0.0
Accumulated other comprehensive loss	(329.4)	(319.9)
Retained earnings	16,107.7	15,071.6
Treasury stock, at cost	(2,977.1)	(2,611.7)
Total Biogen Inc. shareholders’ equity	12,860.5	12,140.1
Noncontrolling interests	(11.6)	(11.5)
Total equity	12,848.9	12,128.6
Total liabilities and equity	$ 23,073.2	$ 22,876.8